ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

ClinicalTrials.gov ID: NCT02585713

Public ClinicalTrials.gov record NCT02585713. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 7:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism

Study identification

NCT ID
NCT02585713
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Academic and Community Cancer Research United
Other
Enrollment
300 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 19, 2015
Primary completion
Apr 1, 2018
Completion
Dec 23, 2019
Last update posted
Aug 3, 2020

2015 – 2019

United States locations

U.S. sites
18
U.S. states
13
U.S. cities
18
Facility City State ZIP Site status
Mayo Clinic in Arizona Scottsdale Arizona 85259
Mayo Clinic in Florida Jacksonville Florida 32224-9980
NorthShore University HealthSystem-Evanston Hospital Evanston Illinois 60201
Illinois CancerCare-Peoria Peoria Illinois 61615
University of Iowa/Holden Comprehensive Cancer Center Iowa City Iowa 52242
Siouxland Regional Cancer Center Sioux City Iowa 51101
Cancer Center of Kansas - Wichita Wichita Kansas 67214
Cancer Research Consortium of West Michigan NCORP Grand Rapids Michigan 49503
Mayo Clinic Rochester Minnesota 55905
Coborn Cancer Center at Saint Cloud Hospital Saint Cloud Minnesota 56303
Metro Minnesota Community Oncology Research Consortium Saint Louis Park Minnesota 55416
University of Nebraska Medical Center Omaha Nebraska 68198
New Hampshire Oncology Hematology PA-Hooksett Hooksett New Hampshire 03106
FirstHealth of the Carolinas-Moore Regional Hosiptal Pinehurst North Carolina 28374
Columbus NCI Community Oncology Research Program Columbus Ohio 43215
Toledo Clinic Cancer Centers-Toledo Toledo Ohio 43623
Guthrie Medical Group PC-Robert Packer Hospital Sayre Pennsylvania 18840
Rapid City Regional Hospital Rapid City South Dakota 57701

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02585713, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 3, 2020 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02585713 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →